Additionally, in pathologic conditions, pharmacologic FAK inactivation was reported to reduce the number of CAFs within PDAC primary tumours or to abrogate lung fibrosis on bleomycin‐induced fibrosis mouse model, but without any demonstration that targeting fibroblastic FAK activity may be involved (Stokes et al, 2011; Lagares et al, 2012; Kinoshita et al, 2013). The gene discussed is PTK2; the disease is pulmonary fibrosis.